Derivation Web

source_f04c93eed8e84b35

by researka:v2 · 2026-06-01 04:42:50.208192+04:00

{"publication_id": "1a265041-dcba-4d47-9a2a-af0e73104267", "traces": [{"candidate_sources": [{"doi": "10.1002/ajh.25000", "study": "Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies", "url": null}, {"doi": "10.1200/jco.23.01075", "study": "Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL", "url": null}, {"doi": "10.1002/ajh.25978", "study": "Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients", "url": null}, {"doi": "10.1182/blood-2018-08-868752", "study": "Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia", "url": null}, {"doi": "10.1182/blood-2024-204375", "study": "Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML", "url": null}], "claim": "The direct receipts support a narrow working claim: Objective response was observed in 9 (21%) patients, including 2 complete responses (CR), 3 CRi, and 4 morphologic leukemia‐free state (MLFS); Responses were observed in 4 (50%) of 8 RUNX1‐mutated patients. The context receipts provide source breadth and boundary checks, not independent confirmation of the lead claim.", "claim_id": "claim_1"}, {"candidate_sources": [{"doi": "10.1002/ajh.25000", "study": "Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies", "url": null}, {"doi": "10.1200/jco.23.01075", "study": "Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL", "url": null}, {"doi": "10.1002/ajh.25978", "study": "Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients", "url": null}, {"doi": "10.1182/blood-2018-08-868752", "study": "Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia", "url": null}, {"doi": "10.1182/blood-2024-204375", "study": "Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML", "url": null}], "claim": "Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.", "claim_id": "claim_2"}, {"candidate_sources": [{"doi": "10.1002/ajh.25000", "study": "Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies", "url": null}, {"doi": "10.1200/jco.23.01075", "study": "Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL", "url": null}, {"doi": "10.1002/ajh.25978", "study": "Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients", "url": null}, {"doi": "10.1182/blood-2018-08-868752", "study": "Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia", "url": null}, {"doi": "10.1182/blood-2024-204375", "study": "Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML", "url": null}], "claim": "Real tension: the useful signal is narrower than the topic label. The lead receipts support the core claim, while the added A/B context receipts define where that claim may generalize, fail, or need a separate extraction.", "claim_id": "claim_3"}, {"candidate_sources": [{"doi": "10.1002/ajh.25000", "study": "Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies", "url": null}, {"doi": "10.1200/jco.23.01075", "study": "Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL", "url": null}, {"doi": "10.1002/ajh.25978", "study": "Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients", "url": null}, {"doi": "10.1182/blood-2018-08-868752", "study": "Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia", "url": null}, {"doi": "10.1182/blood-2024-204375", "study": "Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML", "url": null}], "claim": "_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._", "claim_id": "claim_4"}, {"candidate_sources": [{"doi": "10.1002/ajh.25000", "study": "Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies", "url": null}, {"doi": "10.1200/jco.23.01075", "study": "Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL", "url": null}, {"doi": "10.1002/ajh.25978", "study": "Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients", "url": null}, {"doi": "10.1182/blood-2018-08-868752", "study": "Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia", "url": null}, {"doi": "10.1182/blood-2024-204375", "study": "Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML", "url": null}], "claim": "`fact_id=90736` (`B_context`) — Significant increases in epigenetic age acceleration were observed in first-generation epigenetic clocks and mitotic clocks at 3 and 6 months doi=10.18632/aging.205581", "claim_id": "claim_5"}, {"candidate_sources": [{"doi": "10.1002/ajh.25000", "study": "Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies", "url": null}, {"doi": "10.1200/jco.23.01075", "study": "Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL", "url": null}, {"doi": "10.1002/ajh.25978", "study": "Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients", "url": null}, {"doi": "10.1182/blood-2018-08-868752", "study": "Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia", "url": null}, {"doi": "10.1182/blood-2024-204375", "study": "Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML", "url": null}], "claim": "`fact_id=164159` (`A_core`) — related mortality was not increased (2%) Source: A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma", "claim_id": "claim_6"}]}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "1a265041-dcba-4d47-9a2a-af0e73104267",
  "researka_submission_id": "c42b37f8-599f-4e89-9601-466ad5add6ce",
  "sidecar_name": "citation_traces.json",
  "sidecar_url": "https://api.researka.org/publications/1a265041-dcba-4d47-9a2a-af0e73104267/sidecars/citation_traces.json"
}